Cerebrospinal Fluid Levels of Kininogen-1 Indicate Early Cognitive Impairment in Parkinson's Disease

Mov Disord. 2020 Nov;35(11):2101-2106. doi: 10.1002/mds.28192. Epub 2020 Aug 15.


Background: Cognitive impairment is common in patients with PD. Core markers of Alzheimer's dementia have been related also to PD dementia, but no disease-specific signature to predict PD dementia exists to date.

Objectives: The aim of this study was to investigate CSF markers associated with cognition in early PD.

Methods: A high-throughput suspension bead array examined 216 proteins in CSF of 74 PD patients in the AETIONOMY project. Cognitive function was assessed with Repeatable Battery for the Assessment of the Neuropsychological Status, Montreal Cognitive Assessment, and Mini-Mental State Examination.

Results: Of 69 patients with complete data, 34 had high (≥90) and 35 had low Repeatable Battery for the Assessment of the Neuropsychological Status total score (<90). Of 14 proteins in CSF that differed in levels between groups, increased kininogen-1, validated with several antibodies, was independently associated with lower Repeatable Battery for the Assessment of the Neuropsychological Status and Montreal Cognitive Assessment scores after adjustment for confounders.

Conclusions: Kininogen-1 levels in CSF may serve as a marker of cognitive impairment in PD. © 2020 The Authors. Movement Disorders published by Wiley Periodicals LLC on behalf of International Parkinson and Movement Disorder Society.

Keywords: Parkinson's disease; cognition; kininogen-1; neurodegeneration.

Publication types

  • Research Support, Non-U.S. Gov't

MeSH terms

  • Cognition Disorders* / diagnosis
  • Cognition Disorders* / etiology
  • Cognitive Dysfunction* / etiology
  • Humans
  • Kininogens
  • Mental Status and Dementia Tests
  • Neuropsychological Tests
  • Parkinson Disease* / complications


  • KNG1 protein, human
  • Kininogens